mpec
To be blunt, the impression I’ve gained is that the institutions don’t “rate” trofinetide.
When the licensing deal was signed with Acadia in 2018, the influential EvaluatePharma delivered a rather scathing assessment of both Bell Potter and the potential value of trofinetide.
More recently, there was a telling off-the-cuff comment made by an analyst during the Acadia Q4 2019 Earnings Call held in February. Asking a question on trofinetide and the Lavender study, the Cantor Fitzgerald analyst confidently predicted that this was “an asset that I'm sure you won't get any other questions on”. And he was right. His was the only question on trofinetide.
Compare this with Acadia’s latest Earnings Call when three analysts had keen interest in and questions about Acadia’s newly licensed preclinical assets from Vanderbilt....
ACADIA TALKS TROFINETIDE, page-68
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |